Long-term Anti-VEGF Suppression of Radiation Retinopathy is Possible
Very Important News!
“Untreated, macular radiation retinopathy typically leaves the eye with poor vision or legally blind. But if this happens to you, drug therapy preserve vision."
Ophthalmic radiation therapy continues to save the lives, vision and eyes for cancer patients. However, eyes with intraocular tumors posterior to the equator, or in the macula and large tumors often develope sight-limiting radiation retinal damage. However, intraocular anti-VEGF therapy with a dose escalation strategy can be used for vision preservation.
This month, Dr. Finger and colleagues (From The New York Eye Cancer Center) reported their 10-year experience using anti-VEGF drugs to preserve vision for patients with retinal radiation damage. Like so many other diseases (diabetes, hypertension, heart disease and arthritis) radiation maculopathy has been pharmacologically suppressed and transformed into a manageable event. This is the first "long-term" experience reported on this technique.
In 2005, the first patient was treated by Dr. Finger in 2005. Since then, Drs. Finger, Chin and Semenova (from The New York Eye Cancer Center) embarked on a 10-year prospective study. Dr. Finger is pleased to note, "Our excellent and remarkable long-term results have just been published in the European Journal of Ophthalmology."
Receive the latest news and opportunities from The Eye Cancer Foundation. Please fill out the form below.